Introduction {#sec1_1}
============

Although the incidence of poststernotomy mediastinitis is low and is reported to range from 0.5 to 5%, it is a potentially devastating complication of cardiac surgery, and is associated with increased mortality, morbidity and cost \[[@B1],[@B2],[@B3]\]. In addition, the great number of cardiac operations performed all over the world and the high rate of mortality associated with mediastinitis (20--33%) make this infection an important topic for study \[[@B4],[@B5],[@B6],[@B7]\].

Mediastinitis secondary to cardiothoracic surgery is primarily caused by Gram-positive cocci, and staphylococci are responsible for infection in \>60% of cases \[[@B1],[@B8]\]. Risk factors for poststernotomy mediastinitis have been analyzed in numerous studies, and these include diabetes mellitus, obesity, emergency surgery, heart transplant surgery, complex surgery, the use of internal mammary arteries in coronary artery bypass grafting (CABG), a prolonged operative time, blood transfusion and the indiscriminate use of electrocautery \[[@B1],[@B9]\].

Several studies have identified the risk factors leading to death in patients with poststernotomy mediastinitis \[[@B4],[@B5],[@B6],[@B7]\]. In this study, we analyzed the risk factors for mortality over a 9-year period in a group of 117 patients who developed mediastinitis after open heart surgery.

Subjects and Methods {#sec1_2}
====================

All adult patients who underwent a sternotomy at the Siyami Ersek Thoracic and Cardiovascular Surgery Hospital from 1 January 2004 to 30 June 2012 and who developed mediastinitis were included in the study. Surveillance of sternal surgical-site infections was conducted throughout the study period using a patient- and laboratory-based surveillance method. The US Centers for Disease Control and Prevention (CDC) criteria for mediastinitis were used in the diagnosis \[[@B10]\]. Due to the presence of a foreign body (sternal wire) in the sternum after the sternotomy, patients with mediastinitis that occurred in the first postoperative year were included in the study.

Data used for the risk factor analysis were retrospectively obtained from the hospital database. The following variables were recorded: age, gender, American Society of Anesthesiologists (ASA) score, comorbid conditions before sternotomy (diabetes mellitus, chronic renal failure or congestive heart failure), type of operation, operative and postoperative characteristics \[type of bypass grafts used, intra-aortic balloon pump (IABP) and vasopressor usage\], the duration of the stay in the intensive-care unit (ICU), a second surgical intervention for bleeding or tamponade before infection, the causative microorganisms, the results of wound and blood culture, the time between surgery and the diagnosis of mediastinitis, antibiotic regimens, the duration of the second surgical intervention for infection and the time between infection and death, laboratory values (levels of blood sugar, blood urea nitrogen, creatinine, C-reactive protein, serum aspartate aminotransferase and hemoglobin, and platelet and white blood cell counts) at the time of diagnosis of the infection, the type of second surgical intervention for infection \[standard therapy with primary closure, standard therapy with Robicsek closure (bilateral and longitudinal parasternal wiring) or omental/muscle flap\], the use of a wound vacuum (VAC) for treatment and the total length of hospital stay. During the study period, the standard surgical therapy for poststernotomy mediastinitis at our hospital was sternal debridement and drainage, with either a primary or Robicsek closure technique. In the case of suspected mediastinitis, blood and sternal drainage cultures were obtained from patients and empirical antibiotics were subsequently prescribed, usually consisting of vancomycin and an agent that was active against Gram-negative rods (e.g. cefoperazone + sulbactam, ciprofloxacin or imipenem). Antibiotics were deescalated according to the culture and sensitivity results. The minimum inhibitory concentration of methicillin-resistant *Staphylococcus aureus* (MRSA) strains had not yet been determined between 2004 and 2008, and daptomycin was not available in Turkey until 2010. Since all of the MRSA isolates were found to be resistant to rifampicin and gentamicin during our study period, vancomycin alone was used to treat all except for 3 patients with MRSA mediastinitis. Due to its nephrotoxic side effects, vancomycin was changed to teicoplanin for 2 patients, even though the standard dose of teicoplanin can be less efficacious than vancomycin against MRSA \[[@B11]\]. Linezolid, a bacteriostatic agent, was used for 1 patient.

MRSA-specific infection control interventions that were undertaken during the study period from 2004 to 2012, along with general infection control measures at different time intervals were the surveillance of MRSA sternal surgical-site infections and feedback, preoperative nasal MRSA screening, decolonization with mupirocin and isolation of patients infected with or colonized by MRSA. Information about the infection control interventions that were undertaken to decrease the rate of sternal surgical-site infections in our hospital has been reported previously \[[@B12]\]. Mortality was defined as inhospital death. Mediastinitis was regarded as the sole reason for death if it was the first serious complication during the postoperative period, and it was regarded as contributing to death if it followed other serious complications such as bleeding or central nervous system complications during the postoperative period.

Statistical analyses were done using SPSS for Windows, version 16.0. The χ^2^ and Student t tests were used for the univariate analysis of categorical and continuous variables of patient characteristics, respectively. Independent risk factors for mortality were determined by multiple logistic regression analysis. Variables found to be significant (p \< 0.05) in the univariate analysis or reported to be risk factors for mortality in the literature were included in the logistic regression analysis.

Results {#sec1_3}
=======

Open heart surgery was performed on 19,767 patients. This surgery included CABG in 13,628 (69%) patients, valve replacement in 3,481 (18%), aortic surgery in 1,098 (18%), valve replacement and CABG in 773 (4%) and other operations in 787 (4%). The mean time from the first operation to infection occurrence was 13.37 ± 6.74 days (range 3--32). One hundred and seventeen patients (0.59%) were diagnosed with mediastinitis; bacteremia developed in 56 (48%) of these. The causative microorganisms and their respective bacteremia and mortality rates are shown in table [1](#T1){ref-type="table"}. Of the 117 patients, 38 (32%) died during their hospital stay or upon readmission to the hospital. The mortality rate was highest for mediastinitis caused by MRSA (23/49 cases or 49%) and lowest for that caused by coagulase-negative staphylococci (2/15 cases or 11%). The duration (mean ± SD) from the beginning of infection to death was 45.42 ± 102.29 days (median 17.5 and range 1--630). Mediastinitis was the sole cause of death in 15 patients (40%) and contributed to death in 23 (60%). Infective endocarditis was diagnosed in 6 of the 117 patients as a complication of bacteremic mediastinitis. One of these 6 patients had definite and 5 had probable concomitant infective endocarditis, according to the Duke criteria. Patients with a diagnosis of endocarditis secondary to bacteremic mediastinitis did not undergo redo valve replacement surgery because of the unacceptably high rate of operative mortality. The ASA scores of patients did not differ during the study period (p = 0.091).

Based on the univariate analysis, risk factors for mortality with mediastinitis were female gender, an ASA score ≥3, congestive heart failure before surgery, any operation other than CABG, any operation involving valve replacement, an ICU stay \>48 h after the first operation, vasopressor and IABP usage after the first operation, blood urea nitrogen and creatinine levels and platelet count at the diagnosis of infection, mediastinitis caused by MRSA, the development of probable or definite concomitant infective endocarditis and the duration of appropriate antibiotic treatment (p \< 0.05; table [2](#T2){ref-type="table"}).

Based on the multivariate analysis, the independent risk factors for mortality with mediastinis were MRSA as the causative agent \[odds ratio (OR) 12.11 and 95% confidence interval (CI) 3.15--46.47\], an ICU stay \>48 h after the first operation (OR 11.21 and 95% CI 3.24--38.84) and surgery including valve replacement (OR 6.2 and 95% CI 1.44--27.13; p \< 0.05; table [3](#T3){ref-type="table"}).

A comparison of the characteristics of patients with and without MRSA infection did not reveal any difference between the groups (p \> 0.05) except for rates of bacteremia (p \< 0.001) and mortality (p = 0.002) which were higher in the MRSA group.

MRSA infections at the sternal surgical site decreased significantly in 2009 owing to the effectiveness of the continuous infection control program at our hospital. The mortality rate also decreased significantly, from 35% (34/89) between 2004 and 2008 to 14% (4/28) between 2009 and 2012 (p = 0.018). The rate of MRSA mediastinitis among patients after open heart surgery, the rate of preoperative nasal MRSA, the proportion of all hospital nosocomial infections caused by MRSA and the mortality and MRSA rates among mediastinitis cases are shown in figure [1](#F1){ref-type="fig"}.

None of the variables analyzed for mortality risk were significantly different between the patients who underwent surgery before MRSA mediastinitis was eliminated in 2009 and those who underwent surgery after this (p \> 0.05), except for MRSA (p = 0.000), female gender (p = 0.029) and mortality rates (p = 0.018).

Discussion {#sec1_4}
==========

The 32% overall mortality rate after median sternotomy mediastinitis in our study is similar to the rate reported in other recent studies \[[@B4],[@B5],[@B6]\]. We also showed that MRSA infection was an independent risk factor for inhospital mortality due to poststernotomy mediastinitis. Previous reports have also described MRSA infection as an independent risk factor for death, increased mortality and treatment failure linked to poststernotomy mediastinitis, even when compared to methicillin-susceptible *S. aureus* infection \[[@B6],[@B13],[@B14],[@B15],[@B16],[@B17]\]. Morisaki et al. \[[@B15]\] showed that MRSA infection was the factor most strongly associated with increased inhospital mortality, and Karra et al. \[[@B6]\] reported it to be the factor most strongly associated with 1-year mortality after poststernotomy mediastinitis. MRSA infections have been endemic in our hospital since 1995. Based on an epidemiological analysis \[[@B18]\], infection control interventions were initiated in 1998. However, it took some time for all of the interventions to be implemented, so MRSA infections were not completely controlled until 2009 \[[@B12]\]. Although nosocomial infections (mainly pneumoniae) caused by MRSA occur infrequently, we did not see any mediastinitis caused by MRSA after 2008 (fig. [1](#F1){ref-type="fig"}). The mortality rate of mediastinitis also dropped significantly after 2008. This decline further supports the notion that MRSA is an independent risk factor for mortality in patients with mediastinitis.

The reasons for the increased mortality rate among patients with MRSA infections are not clearly understood. There is no evidence to suggest that MRSA strains are more virulent than methicillin-susceptible *S. aureus* strains, although there is evidence to suggest that vancomycin may be an inferior antistaphylococcal antibiotic compared to semisynthetic penicillins, especially for the treatment of deep-seated *S. aureus* infections \[[@B19]\]. Based on the finding of higher mortality rates from mediastinitis due to MRSA in our study and as mentioned in earlier studies and the current lack of highly active anti-MRSA antimicrobials, this microorganism is considered to be dangerous, in particular for patients undergoing cardiac surgery. Hence, every effort should be made to eradicate MRSA infections from cardiac-surgery units.

The finding that valve replacement surgery is an independent risk factor for mortality in patients with mediastinitis in our study is similar to other studies \[[@B5],[@B20]\]. A probable reason for the high mortality rate in mediastinitis with valve replacement surgery might be the severity of the underlying illness. In our study, the ASA scores were higher in patients with valve replacement surgery than in patients with other types of open heart surgery. In addition, even in the absence of any complication, the expected mortality rates of 5% with valve replacement surgery and 10% with combined CABG and valve replacement surgery are higher than the 2% when CABG surgery only is performed \[[@B21]\]. Forty percent of our patients with valve replacement surgery underwent simultaneous CABG. The addition of mediastinitis to the picture could have caused an even higher mortality rate after this combined surgery, which is already associated with a high mortality rate.

Another reason for the high mortality rate in patients with valve replacement surgery and mediastinitis could be the development of endocarditis secondary to the mediastinitis. While the univariate analysis showed that the development of infective endocarditis is a risk factor for mortality, the multivariate analysis did not confirm this. Infective endocarditis was diagnosed in 6 of our patients. In patients with mediastinitis, prosthetic valves can be infected either by direct inoculation from the infected mediastinum or during concurrent bacteremia. The high rate of 50% bacteremia in patients with mediastinitis in our study confirmed that reported by Mekontso-Dessap et al. \[[@B13]\]. Unfortunately, once established, prosthetic-valve endocarditis leads to death in almost half of patients; this occurs particularly in cases of nosocomial infection \[[@B22],[@B23]\]. These data underline the importance of preventing mediastinitis (and bacteremia) in patients with prosthetic valves.

Our finding that a longer stay in ICU after the first operation is associated with increased mortality is similar to that of another study \[[@B6]\]. This could probably be a marker for patients with increased immediate perioperative complications, such as bleeding, organ failure, hypotension, neurologic sequelae or second surgical intervention, which predispose such patients to mediastinitis and death. Patients who experience these complications and have to stay in the ICU for longer periods deserve special attention in order to prevent infectious complications and high mortality rates as a consequence.

VAC therapy \[[@B24]\] has been reported to be efficient in the treatment of poststernotomy mediastinitis. We used the procedure on 3 patients, and all of them survived; however, this is a small number, so we were not able to compare standard therapy with VAC usage in the treatment of mediastinitis.

Our study has some limitations. Although the diagnoses of mediastinitis were made prospectively, variables were retrieved retrospectively from hospital records, and so some variables that might have been associated with death after mediastinitis could not be included in the study. The minimal inhibitory concentrations of MRSA strains and the levels of vancomycin in the blood of patients with MRSA mediastinitis treated with this drug could not be determined during the study period. This meant it was not possible for us to determine whether or not the high mortality rate in these patients was actually due to inefficient treatment of the MRSA infection with vancomycin.

Conclusion {#sec1_5}
==========

In this study, MRSA was an independent risk factor of mortality in poststernotomy mediastinitis. Elimination of MRSA from our hospital decreased the rate of mortality in poststernotomy mediastinitis. Mediastinitis was also associated with an increased risk for patients undergoing valve replacement surgery.

![The rates of mortality and MRSA in cases of mediastinitis, the rate of MRSA mediastinitis after open heart surgery and the incidence of all nosocomial infections caused by MRSA during the study period.](mpp-0023-0517-g01){#F1}

###### 

Bacteremia and inhospital mortality in mediastinitis patients, according to the causative microorganism

  Causative microorganism             n (%)       Bacteremia, n (%)   Mortality, n (%)
  ----------------------------------- ----------- ------------------- ------------------
  MRSA                                47 (40)     32 (68)             23 (49)
  Enterobacteriaceae                  21 (18)     10 (48)             6 (29)
  Coagulase-negative staphylococci    19 (16)     3 (15)              2 (11)
  Methicillin-sensitive *S. aureus*   13 (11)     4 (30)              2 (15)
  Others                              17 (15)     7 (41)              5 (29)
                                                                      
  Total                               117 (100)   56 (48)             38 (32)

###### 

Characteristics of mediastinitis patients with and without mortality

  Characteristics                                                                   Patients without mortality (n = 79)   Patients with mortality (n = 38)   p
  --------------------------------------------------------------------------------- ------------------------------------- ---------------------------------- ---------------------------------------
  Age, years                                                                        61.10 ± 9.05                          63.07 ± 11.79                      0312
  Female gender                                                                     25 (32)                               21 (55)                            0.014[\*](#T2F1){ref-type="table-fn"}
  ASA score ≥3                                                                      39 (49)                               28 (74)                            0.013[\*](#T2F1){ref-type="table-fn"}
  Diabetes mellitus                                                                 32 (41)                               21 (55)                            0.133
  Congestive heart failure                                                          5 (6)                                 14 (37)                            0.000[\*](#T2F1){ref-type="table-fn"}
  Chronic renal failure                                                             3 (4)                                 2 (5)                              0.656
  Type of operation                                                                                                                                          
  Operation other than CABG                                                         18 (23)                               18 (47)                            0.007[\*](#T2F1){ref-type="table-fn"}
  Surgery involving valve replacement                                               6 (8)                                 15 (39)                            0.000[\*](#T2F1){ref-type="table-fn"}
  Left internal mammary artery usage                                                68 (86)                               30 (79)                            0.422
  ICU stay \>48 h after the first operation                                         16 (20)                               26 (68)                            0.000[\*](#T2F1){ref-type="table-fn"}
  IABP usage after the first operation                                              5 (6)                                 8 (21)                             0.029[\*](#T2F1){ref-type="table-fn"}
  Vasopressor usage after the first operation                                       12 (15)                               20 (53)                            0.000[\*](#T2F1){ref-type="table-fn"}
  Second surgical intervention for bleeding during immediate postoperative period   11 (14)                               10 (26)                            0.130
  Readmission to the hospital with infection                                        31 (39)                               8 (21)                             0.051
  Time from first operation to infection, days                                      13.05 ± 6.51                          14.05 ± 7.23                       0.472
  Causative microorganisms                                                                                                                                   
   MRSA (vs. others)                                                                24 (30)                               23 (60)                            0.002[\*](#T2F1){ref-type="table-fn"}
   Gram-positive (vs. Gram-negative)                                                54 (68)                               26 (68)                            0.835
  Presence of bacteremia                                                            34 (43)                               22 (58)                            0.132
  Development of probable or definite concomitant infective endocarditis            1 (1.3)                               5 (12.8)                           0.014[\*](#T2F1){ref-type="table-fn"}
  Hemoglobin level at the time of infection diagnosis, g/dl                         9.95 ± 1.38                           10.39 ± 1.44                       0.123
  White blood cell count at the time of infection diagnosis, per μl                 15,000 ± 6,189                        15,095 ± 5 565                     0.413
  Thrombocytopenia (\<150,000/mm^3^)                                                5 (6)                                 11 (29)                            0.003[\*](#T2F1){ref-type="table-fn"}
  Blood sugar level at the time of infection diagnosis, mg/dl                       160.22 ± 78.56                        162.82 ± 68.87                     0.856
  BUN level at the time of infection diagnosis, mg/dl                               26.93 ± 14.19                         40.05 ± 25.01                      0.004[\*](#T2F1){ref-type="table-fn"}
  Creatinine level at the time of infection diagnosis, mg/dl                        1.16 ± 0.61                           1.52 ± 0.86                        0.024[\*](#T2F1){ref-type="table-fn"}
  SGPT level at the time of infection diagnosis, U/l                                66.62 ± 130.53                        126.14 ± 509.03                    0.481
  Second surgical intervention for infection                                                                                                                 
   None                                                                             16 (20)                               8 (21)                             0.550
   Standard therapy with primary closure                                            41 (52)                               20 (53)                            0.941
   Standard therapy with Robicsek closure                                           19 (24)                               8 (21)                             0.719
  Omental/muscle flap                                                               3 (4)                                 2 (5)                              0.714
  VAC performed                                                                     3 (4)                                 0 (0)                              0.304
  Time for second surgical intervention, days                                       7.98 ± 19.11                          6.44 ± 7.15                        0.676
  Time for appropriate antibiotic treatment, h                                      27.32 ± 26.45                         55.36 ± 64.14                      0.027[\*](#T2F1){ref-type="table-fn"}
  Mediastinitis before MRSA infection control                                       55 (70)                               34 (89)                            0.018[\*](#T2F1){ref-type="table-fn"}
  Total hospital stay, days                                                         48.83 ± 25.27                         47.97 ± 33.53                      0.889

Values are mean ± SD or n (%). BUN = Blood urea nitrogen.

Statistically significant.

###### 

Results of logistic regression analysis of risk factors of mortality in mediastinitis cases

  Variables                                                         p value   OR       95% CI   
  ----------------------------------------------------------------- --------- -------- -------- --------
  Mediastinitis due to MRSA                                         0.000     12.117   3.159    46.475
  Female gender                                                     0.067     3.064    0.925    10.150
  ICU stay longer than 48 h after the first operation               0.000     11.219   3.240    38.849
  Creatinine level \>1.1mg/dl at the time of infection diagnosis    0.068     3.081    0.919    10.325
  Platelet number \>150,000/μl at the time of infection diagnosis   0.062     4.716    0.926    24.012
  Surgery involving valve replacement                               0.014     6.252    1.441    27.138
